Estela Rutiaga
Family Medicine · Marana, AZNPI 1083876064
Payments from drug & device makers
Across 76 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$221
- Boehringer Ingelheim$205
- Novo Nordisk$121
- Amgen$118
- Pfizer$112
- Novartis$102
- plus $447 from 17 others
What the payments were for
- Food & beverage$1,326100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $221 |
| Boehringer Ingelheim | 11 | $205 |
| Novo Nordisk | 8 | $121 |
| Amgen | 5 | $118 |
| Pfizer | 8 | $112 |
| Novartis | 5 | $102 |
| Abbott | 4 | $82 |
| Lilly USA, LLC | 4 | $61 |
| AstraZeneca | 3 | $42 |
| Dexcom, Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Phadia US Inc. | 2 | $25 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Dynavax Technologies Corporation | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Exact Sciences | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
How this compares
$1,326 in reported general payments places this provider in the 75th percentile of 2,099 family medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $23,238 |
| EliquisApixaban | 19 | $20,823 |
| JardianceEmpagliflozin | 13 | $18,111 |
| TrulicityDulaglutide | 13 | $12,269 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,173 |
| Atorvastatin Calcium | 157 | $1,458 |
| Levothyroxine Sodium | 122 | $1,057 |
| Gabapentin | 44 | $1,055 |
| Losartan Potassium | 68 | $894 |
| Omeprazole | 54 | $825 |
| Pregabalin | 18 | $802 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $617 |
| Rosuvastatin Calcium | 52 | $543 |
| Amlodipine Besylate | 83 | $516 |
| Simvastatin | 59 | $504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $121 | $23,23817 claims |
| PfizerEliquis | $112 | $20,82319 claims |
| Boehringer IngelheimJardiance | $205 | $18,11113 claims |
| Lilly USA, LLCTrulicity | $61 | $12,26913 claims |
| AstraZenecaSymbicort | $42 | $4,17316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Marana
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
- Corey AndersonMesa$21.5M
- Dena PetersenTucson$14.7M
- Gerald ShockeyMesa$12.3M
- Brock MerrittPhoenix$8.4M
- John McGettiganTucson$8.3M
- Neil ShethChandler$6.7M
- Joseph LilloScottsdale$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.